Company Filing History:
3 out of 639 
3 out of 20 Years Active: 2012-2014
Title: Mireille Ainciburu: Innovator in Medical Diagnostics
Introduction
Mireille Ainciburu, an accomplished inventor located in Sussargues, France, has made significant contributions to the field of medical diagnostics. With a total of three patents, her work focuses on alternative gene transcripts related to kallikrein 8, which have implications for understanding and diagnosing bronchopulmonary carcinoma.
Latest Patents
Ainciburu's latest patents include innovative discoveries such as NT5 and NT6, which pertain to the alternative transcripts of the KLK8 gene encoding kallikrein 8. The sequences for NT5 and NT6 are detailed in SEQ ID NO:7 and SEQ ID NO:8, respectively. Additionally, she developed a method for the in vitro diagnosis of bronchopulmonary carcinoma. This method specifically detects the major alternative transcripts of the KLK8 gene in biological samples from patients suspected of having this type of cancer. This breakthrough is particularly beneficial for prognosticating the survival of those suffering from non-small cell bronchial carcinoma.
Career Highlights
Throughout her career, Mireille Ainciburu has worked with notable organizations, including bioMérieux, Inc. and Université François Rabelais. These positions have allowed her to collaborate on critical research projects and advance her innovations in medical science.
Collaborations
Ainciburu has collaborated with prominent individuals, including Yves Courty and Colette Jolivet-Reynaud. These partnerships have undoubtedly contributed to her success and the impactful advancements in her field, reinforcing the importance of teamwork in scientific research.
Conclusion
Mireille Ainciburu exemplifies the spirit of innovation in the medical diagnostics landscape. Her patents, which focus on the KLK8 gene and its relevance to bronchopulmonary carcinoma, pave the way for improved diagnosis and patient prognostication. As she continues her work, her contributions will undoubtedly influence the future of cancer diagnostics and treatment.